Of 672 patients included, 226 (33.6 per cent) had RAS&BRAF wild-type (wt) tumours, 392 (58.3 per cent) RAS mutation (mt) tumours, and 54 (8.0 per cent) BRAFmt tumours. The gene discussed is BRAF; the disease is neoplasm.